NCT01904383已完成不适用
Post Marketing Surveillance on Long Term Drug Use of Trazenta® Tablets as add-on Therapy in Patients With Type 2 Diabetes Mellitus
适应症
干预措施
相关药物
试验速览
- 阶段
- 不适用
- 状态
- 已完成
- 入组人数
- 4,057
- 主要终点
- Percentage of Participants With Drug Related Adverse Events
研究概览
简要总结
Study to investigate the safety and efficacy of long-term daily use of Trazenta® Tablets as add-on therapy in patients with type 2 diabetes mellitus.
研究设计
- 研究类型
- Observational
- 观察模型
- Cohort
- 时间视角
- Prospective
入排标准
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- 未提供
排除标准
- 未提供
研究组 & 干预措施
Trazenta
干预措施: Trazenta (Drug)
结局指标
主要结局
Percentage of Participants With Drug Related Adverse Events
时间窗: From first drug administration until last drug administration, up to approximately 156 weeks.
Percentage of participants with drug related adverse events.
次要结局
- The Mean Change From Baseline to Last Observation of the Treatment Period in Haemoglobin A1c (HbA1c)(Baseline (before administration of treatment) and last observation of the treatment period; up to 156 weeks.)
研究者
相似试验
已完成
不适用
Long-term Daily Use of Trazenta® Tablets in Patients With Type 2 Diabetes MellitusDiabetes Mellitus, Type 2NCT01650259Boehringer Ingelheim4,876
已完成
不适用
Post Marketing Surveillance (PMS) of JARDIANCE in Chronic Heart Failure (CHF)Heart FailureNCT05262764Boehringer Ingelheim1,200
已完成
不适用
Alogliptin Tablets Special Drug Use Surveillance "Type 2 Diabetes Mellitus: Combination Therapy With Thiazolidinediones"Type 2 Diabetes MelitusNCT01945242Takeda1,374
已完成
不适用
Alogliptin Tablets Special Drug Use Surveillance Type 2 Diabetes Mellitus: Combination Therapy With SulfonylureaSurveillanceNCT01964950Takeda1,101
已完成
不适用
Post Marketing Surveillance Study in Rehabilitation Clinics (Cardio, Nephro, Diabetes, Pulmo)HypertensionNCT02262611Boehringer Ingelheim266